AXA Framlington Biotech Fund aims to offer long-term capital appreciation by investing in companies involved in biotechnology, genomic and medical research globally. But, given that most of these companies tend to be in the US, the fund's geographical breakdown is concentrated here with close to 84 per cent of its assets. The rest of the fund's holdings are spread between the UK and Israel with smaller allocations to the rest of Europe.
Gemma Game has managed the fund, along with the Axa Framlington Health Fund, since 2010, having joined the group from BlackRock, where she was a portfolio manager on the global equities team responsible for the healthcare sector. Ms Game graduated from Cambridge University in 2001 where she read Pharmacology.